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Abstract
Background:  The association between coeliac disease (CD) and neoplasms has been long
established, but few data are available about the risk factors. The aim of this paper is to estimate
the risk of developing a neoplasm among non diagnosed coeliac patients and to evaluate if this risk
correlates with the age of patients at diagnosis of coeliac disease.
Methods: The study population consists of patients (n = 1968) diagnosed with CD at 20 Italian
gastroenterology referral Centers between 1st January 1982 and 31st March 2005.
Results: The SIR for all cancers resulted to be 1.3; 95% CI = 1.0–1.7 p < 0.001. The specific SIRs
for non Hodgkin lymphoma was 4.7; 95% CI = 2.9–7.3 p < 0.001, for the small bowel carcinoma
25; 95% CI = 8.5–51.4 p < 0.001, for non Hodgkin lymphoma 10; 95% CI = 2.7–25 p = 0.01, finally
for the stomach carcinoma 3; 95% CI = 1.3–4.9 p < 0.08. The mean age at diagnosis of CD of
patients that developed sooner or later a neoplasm was 47,6 ± 10.2 years versus 28.6 ± 18.2 years
of patients who did not.
Conclusion: Coeliac patients have an increased risk of developing cancer in relation to the age of
diagnosis of CD. This risk results higher for malignancies of the gastro-intestinal sites. An accurate
screening for tumors should be performed in patients diagnosed with CD in adulthood and in
advancing age.
Background
Coeliac disease (CD) is a permanent autoimmune enter-
opathy triggered by the ingestion of gluten, the storage
protein complex of wheat, rye and barley. Gluten causes,
in genetically determined individuals carryng the HLA-
DQ2/DQ8 haplotype, an inflammatory response of the
small bowel mucosa, resulting in villous atrophy, infiltra-
tion of T-lymphocytes and hyperplasia of the cripts. The
only known treatment for this disorder is the life – long
withdrawn from the diet of the above mentioned cereals.
CD occurs worldwide and its prevalence is estimated
about 1/150 individuals [1-3].
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The association between CD and neoplasms has been
long established [4]. In the '60s, a population-based study
has already reported a 100-fold increased risk of non-
Hodgkin's lymphoma in patients affected by CD [5].
More recently, this risk has been resized to 3-fold by an
Italian study and 9-fold by a study from States [6,7].
It has been also noted that CD patients have a higher risk
of developing a small bowel adenocarcinoma respect to
the general population and this neoplasm is the second
invasive malignancy for incidence in these patients [7-10].
In contrast, several studies have shown a lower risk of
breast cancer in patients affected by CD [11-13].
An increased mortality due to cancer in patients with CD
has been also described [14,15]. There are considerable,
but not definitive, evidences that the strict compliance to
gluten-free diet is protective against the development of
malignancies [16-18].
We carried out a perspective, population-based study on
1968 coeliac patients with the aim to evaluate the malig-
nancy risk of developing a malignancy and to assess if the
delayed diagnosis of coeliac disease and the consequent
prolonged dietary exposure to gluten increase the risk of
developing a neoplasm.
Methods
The Italian Registry of the complications of coeliac disease
The Italian Registry of the complications of coeliac disease
was established at Istituto Superiore di Sanità, Rome in
1982. It is the largest database of coeliac patients in Italy.
It contains the files of the coeliac patients referring to 20
Italian Gastroenterology Centers (collaborating Centers).
The Istituto Superiore di Sanità, Rome, Italy provided a
validate form in order to ensure uniformity in collecting
data. The information about sex, date of birth, duration of
symptoms before diagnosis and presence of malignancies
were obtained upon the diagnosis of CD. All the filled
forms were sent to Istituto Superiore di Sanità, where the
data were entered in an electronic database (MS Access).
Study population
The study population consists of the patients diagnosed
with CD at Collaborating Centers between 1st January
1982 and 31st March 2005. All the patients were diag-
nosed with coeliac disease according to the National Insti-
tute of Health (NIH) criteria, including histological
evidence of atrophy of small bowel mucosa and serologi-
cal positivity for EmA and/or anti-tTg Ab (for the patients
diagnosed after 1997) [19].
As our measure of relative risk we used overall and site-
specific standardized incidence ratio (SIR) of cancer. We
calculated the expected number of malignancies in each
sex and 5-years stratum of our population by multiplying
the number of patients in each stratum by site specific
incidence rate from WHO Globoscan 2002 [20]. This
database contains the annual incidence and prevalence
rates of site specific malignancies in each World Countries
according to age and sex.
Statistical analysis
For the total cancers and for the most frequent localiza-
tions, the Standardized Incidence Ratio (SIR, ratio of the
observed to the expected cases) was calculated, along with
the 95% confidence interval, assuming a Poisson distribu-
tion of the population. We stratified the standardized
morbidity ratio by the specific type of malignancy. The
statistical analysis performed by SPSS software.
The collection of data have been approved by Istituto
Superiore di Sanità (10959/8916), All the patients
involved in the study signed the authorization for the
handling of personal data and that the data were collected
and stored according to national regulation.
Results
Population
One thousand nine hundred and sixty eight patients were
enrolled. Out of them, 1485 were female, with a ratio
female/male of 2.6. The mean age at diagnosis of CD was
36.2 ± 13.8. years, as shown in Table 1.
Malignancy
Out of 1968 patients, 55 were diagnosed with a cancer
(2.09%) before or simultaneously the diagnosis of CD
versus 42.1 expected (SIR = 1.3; 95%CI = 1.0–1.7). Table
2 shows the malignancies observed and expected in our
population. The most frequent malignancy resulted to be
the gastro-intestinal non Hodgkin's lymphoma (n = 20),
followed by colon carcinoma (n = 7), small bowel adeno-
carcinoma (n = 5), Hodgink's lymphoma (n = 4), stomach
Table 1: Characteristics of 1968 patients with CD
Characteristic Number or Mean ± SD
Female gender 1495
Mean age at diagnosis of CD 36.2 ± 13.8
Mean duration of symptoms before diagnosis of CD 6 ± 2.2BMC Gastroenterology 2007, 7:8 http://www.biomedcentral.com/1471-230X/7/8
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and breast carcinomas (n = 3). Other localizations
included: liver, lung, ovary, thyroid cancer and mieloma
(2 cases each) and acute leukemia, melanoma and uterus
(1 cases each). No patient developed two or more cancers.
Considering the SIR for site-specific malignancies, it
resulted 4.7 for Non-Hodgkin's lymphoma, 26 for small
bowel carcinoma, 3 for the stomach cancer and 10 for the
Hodgkin's lymphoma. The risk for breast cancer resulted
considerably lower than the general population.
The mean age at diagnosis of CD for the patients diag-
nosed with a cancer before o simultaneously was 47,6 ±
10.2 years, as shown in table 3. It was significantly higher
than the age at diagnosis of CD of the patients who did
not develop a malignancy (28.6 ± 18.2 years).
Discussion
This study demonstrates that coeliac patients have an
increased risk of developing cancer in relation to the age
of diagnosis of CD. In fact, the mean age at diagnosis of
CD in the group of patients that developed sooner or later
a cancer is higher than that of patients who did not
develop a cancer. Some Authors have supposed that the
diagnostic delay is a risk factor for developing a malig-
nancy because of the prolonged period of dietary expo-
sure to gluten [15,16]. This risk is more relevant for the
intestine -specific cancers such as small bowel carcinoma
and non Hodking's lymphoma.
No cases of oropharyngeal and esophageal squamous car-
cinoma have been found, although Askling et al reported
a high risk in coeliac population [12]. It is noteworthy
that in the Swedish study, the patients were selected
among those requiring hospitalization, so the severity of
disease was a selection bias to be considered. In addition,
there could be some genetic and environmental factors,
such as the diet, exerting a protective effect towards
tumors of the upper gastrointestinal tract among the Ital-
ian people. As matter of the fact, no excess of non hema-
tological malignancies was found by a previous Italian
population-based study [15].
Small bowel carcinoma is a rare malignancy that usually
arises trough an adenoma-carcinoma sequence [21-23].
However, among our population, only a patient devel-
oped intestinal adenomas. These data did not support the
theory that a premalignant lesion exists between villous
atrophy and small intestine carcinoma, lending support
to previous reports [24]. While small intestine carcinoma
is a male predominant malignancy, four out of the five
patients affected by this cancer were female. Since CD is
prevalent among women, this finding is a further confirm
of the link between small bowel neoplasm and CD.
From a public health perspective, the overall risk of devel-
oping a cancer in coeliac population found in this study
and the uncertain protective effect of gluten free diet do
not support the opportunity of a serological screening for
coeliac disease on general population in order to prevent
a malignancy. But the high mean age at the diagnosis of
CD for the group of patients that developed a cancer sug-
gests that an accurate search for malignancies should be
performed in patients diagnosed with CD as adult and in
the elderly.
This study presents some potential limitation; first of all,
the ascertainment bias. This can only be addressed by a
prospective study with age- and gender- matched controls.
Moreover, all the Clinical Centers involved are tertiary
centers for the diagnosis and treatment of gastrointestinal
diseases. Then, the accurate and frequent clinical controls
the patients with CD use to undergo to, can lead to the
diagnosis of a higher cases of malignancies. So, an excess
of the risk for tumors is likely to be estimated, particularly
that of gastrointestinal sites, since they can be detected
during the endoscopy usually performed for the hystolog-
ical diagnosis of CD [25]. This work considered the inci-
dence of malignancies before and/or simultaneously the
diagnosis of CD only and not during the follow-up. Until
Table 2: Standardized Morbidity Ratio of the site specific malignancies developed before or simultaneously the diagnosis of CD
Cancer Observed Expected SIR(95%CI) p
Cancer for whom CD patients showed a higher risk
Non Hodgkin's lymphoma 20 4.2 4.7 (2.9–7.3) <0.001
Colon 7 6.2 1.1 (0.68–1.56) <0.001
Small bowel 5 0.19 25 (8.5–51.4) <0.001
Hodgkin's lymphoma 4 0.4 10 (2.7–25) 0.01
Stomach 3 1 3 (1.3–4.9) 0.08
Cancer for whom CD patients showed a lower risk
Breast 3 14 0.2 (0.04–0.62) <0.001
Others 13 12 1 (0.9–8.5) 0.06
TOTAL 55 42.1 1.3 (1.0–1.7) 0.001BMC Gastroenterology 2007, 7:8 http://www.biomedcentral.com/1471-230X/7/8
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the diagnosis of CD, the patients do not have more fre-
quent clinical control than healthy population.
Conclusion
This paper confirms that the gluten-free diet is likely to
protect from the development of malignancies in CD
patients, since higher is the age at diagnosis of CD, higher
is the risk of developing a malignancy, Therefore, the
importance of a prompt diagnosis of CD is emphasized.
Our data require to be confirmed by larger population
based studies, but some implications for an accurate
screening for cancers in people with CD are added.
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